Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Umesh Masharani"'
Autor:
José M. Rodriguez‐Valadez, Malak Tahsin, Umesh Masharani, Meyeon Park, M. G. Myriam Hunink, Joseph Yeboah, Lihua Li, Ellerie Weber, Asem Berkalieva, Luuk Avezaat, Wendy Max, Kirsten E. Fleischmann, Bart S. Ferket
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 4 (2024)
Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are mediated by changes in glycated hemoglobin, body weight, systolic blood
Externí odkaz:
https://doaj.org/article/78b10788b725414dbbab332b1f6a1ac1
Autor:
Hope S. Rugo, Mario E. Lacouture, Marcus D. Goncalves, Umesh Masharani, Matti S. Aapro, Joyce A. O'Shaughnessy
Publikováno v:
Breast, Vol 61, Iss , Pp 156-167 (2022)
Purpose: The oral, α-specific phosphatidylinositol-3-kinase (PI3Kα) inhibitor alpelisib is the first PI3K inhibitor approved for the treatment of advanced breast cancer. As alpelisib is a relatively new therapeutic option, specific guidance and a m
Externí odkaz:
https://doaj.org/article/c6c4f39f76af47a99f7d292ece4d71d7
Autor:
Samuel Kou, Carmen De Cunto, Geneviève Baujat, Kelly L. Wentworth, Donna R. Grogan, Matthew A. Brown, Maja Di Rocco, Richard Keen, Mona Al Mukaddam, Kim-Hanh le Quan Sang, Umesh Masharani, Frederick S. Kaplan, Robert J. Pignolo, Edward C. Hsiao
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-10 (2020)
Abstract Background Genetic contributors to cardiac arrhythmias are often found in cardiovascular conduction pathways and ion channel proteins. Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disease of massive heterotopic ossification c
Externí odkaz:
https://doaj.org/article/ecf5cd5133884fc7ab8361ac88baf204
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0151860 (2016)
Testosterone (T) and related androgens are performance enhancing drugs (PEDs) abused by some athletes to gain competitive advantage. To monitor unauthorized androgen abuse, doping control programs use mass spectrometry (MS) to detect androgens, synth
Externí odkaz:
https://doaj.org/article/b6db7de389754937a4783dd4555433fa
Autor:
Elisa Campos, Leila Kotite, Patricia Blanche, Yasushi Mitsugi, Philip H. Frost, Umesh Masharani, Ronald M. Krauss, Richard J. Havel
Publikováno v:
Journal of Lipid Research, Vol 43, Iss 3, Pp 365-374 (2002)
An immunoassay procedure that quantifies remnant-like particle (RLP) cholesterol in human blood plasma has shown considerable promise as a clinically applicable risk marker for atherosclerotic disease. The lipoproteins included in this assay include
Externí odkaz:
https://doaj.org/article/386c339f41fd498f89b0164287ce8b94
Autor:
Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Mathioudakis, Francisco J. Pasquel, Signe Schmidt, Viral N. Shah, Elias K. Spanakis, Andreas Stuhr, Gerlies M. Treiber, David C. Klonoff
Publikováno v:
Journal of diabetes science and technology. 16(5)
The annual Virtual Hospital Diabetes Meeting was hosted by Diabetes Technology Society on April 1 and April 2, 2022. This meeting brought together experts in diabetes technology to discuss various new developments in the field of managing diabetes in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fea85363682cd51c87307984cdad4c34
https://pubmed.ncbi.nlm.nih.gov/35904143
https://pubmed.ncbi.nlm.nih.gov/35904143
Autor:
José M. Rodriguez-Valadez, Malak Tahsin, Kirsten E. Fleischmann, Umesh Masharani, Joseph Yeboah, Meyeon Park, Lihua Li, Ellerie Weber, Yan Li, Asem Berkalieva, Wendy Max, M.G. Myriam Hunink, Bart S. Ferket
Publikováno v:
Diabetes Care, 46(6), 1300-1310. American Diabetes Association Inc.
Diabetes Care
Diabetes Care
BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with diabetes at lower cardiovascular risk, but whether treatment benefits differ by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b39b9ead449ea030b5397d5c9d27527
https://pure.eur.nl/en/publications/d85247f5-eb59-449b-9622-17886569df44
https://pure.eur.nl/en/publications/d85247f5-eb59-449b-9622-17886569df44
Autor:
Nicole Y. Xu, Kevin T. Nguyen, Ashley Y. DuBord, John Pickup, Jennifer L. Sherr, Hazhir Teymourian, Eda Cengiz, Barry H. Ginsberg, Claudio Cobelli, David Ahn, Riccardo Bellazzi, B. Wayne Bequette, Laura Gandrud Pickett, Linda Parks, Elias K. Spanakis, Umesh Masharani, Halis K. Akturk, John S. Melish, Sarah Kim, Gu Eon Kang, David C. Klonoff
Publikováno v:
J Diabetes Sci Technol
Diabetes Technology Society hosted its annual Diabetes Technology Meeting on November 4 to November 6, 2021. This meeting brought together speakers to discuss various developments within the field of diabetes technology. Meeting topics included blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::572bddb4bd32231045122bfdf9b6765e
https://doi.org/10.1177/19322968221090279
https://doi.org/10.1177/19322968221090279
Autor:
Bart S. Ferket, M.G. Myriam Hunink, Umesh Masharani, Wendy Max, Joseph Yeboah, Gregory L. Burke, Kirsten E. Fleischmann
Publikováno v:
Diabetes Care
Diabetes Care, 45(4), 975-982. American Diabetes Association Inc.
Diabetes Care, 45(4), 975-982. American Diabetes Association Inc.
OBJECTIVE To assess lifetime cardiovascular disease (CVD) risk by coronary artery calcium (CAC) score in individuals with diabetes from the Multi-Ethnic Study of Atherosclerosis (MESA) and compare risk with that in individuals without diabetes. RESEA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266c264a2b8509cbe0f133f43e0456e3
https://doi.org/10.2337/dc21-1607
https://doi.org/10.2337/dc21-1607
Autor:
Jose M Rodriguez Valadez, Malak Tahsin, Umesh Masharani, Meyeon Park, M.G. Myriam Hunink, Joseph Yeboah, Lihua Li, Ellerie Weber, Yan Li, Asem Berkalieva, Luuk Avezaat, Wendy Max, Kirsten E Fleischmann, Bart S Ferket
Publikováno v:
Circulation. 147
Background: Prior research suggests cardiovascular (CV) benefits of glucose-lowering interventions may be mediated by changes in hemoglobin A1c (HbA1c), bodyweight, systolic blood pressure (SBP), hematocrit, and urine albumin-creatinine ratio (uACR).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64d4100cc8044a9bf810084e46613b54
https://doi.org/10.1161/circ.147.suppl_1.p140
https://doi.org/10.1161/circ.147.suppl_1.p140